FilingReader Intelligence
Haisco Pharmaceutical plans 965 million yuan share issuance
August 13, 2025 at 08:22 AM UTC•By FilingReader AI
Haisco Pharmaceutical Group plans to issue up to 70 million A shares in a non-public offering to raise up to 1.37 billion yuan.
The proceeds will fund new drug research and development projects (965 million yuan) and supplement working capital (400 million yuan). The issuance requires approval from the Shenzhen Stock Exchange and China Securities Regulatory Commission.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Sponsor letter on the issuance of A shares to specific targets by Hisun Pharmaceutical Group Company Limited by CITIC Securities Company LimitedAugust 13, 2025 at 08:00 AM UTC
Supplementary legal opinion from Beijing Zhong Lun Law Firm regarding the 2025 non-public issuance of A-shares to specific objects by Haisco Pharmaceutical Group Co., Ltd.August 13, 2025 at 08:00 AM UTC
Indicative announcement regarding the reply to the audit inquiry letter concerning the issuance of shares to specific objects and the revision of application documents such as the offering memorandum.August 13, 2025 at 08:00 AM UTC
Sponsor letter for the listing of A-share issuance to specific targets by Haisike Pharmaceutical Group Company Limited by CITIC Securities Company LimitedAugust 13, 2025 at 08:00 AM UTC
Response report to the audit inquiry letter from ShineWing certified public accountants regarding Haisco pharmaceutical group co., ltd.'s application for a private placement of sharesAugust 13, 2025 at 08:00 AM UTC
Reply report to the inquiry letter regarding the application of Haisike Pharmaceutical Group Company Limited for a private placement of sharesAugust 13, 2025 at 08:00 AM UTC
SZSE:002653•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Haisco Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime